The scope of Sanofi Pasteur’s Research & Development activities is vast and complex, encompassing the entire chain of events before a new vaccine becomes available – from understanding a disease and its biological foundations, to clinical development and testing, to obtaining health authorities’ approval for marketing the new vaccine.
We have currently vaccines in development or submitted for approval to meet the specific needs of different segments of the population (influenza, vaccines combination, etc.) or unmet medical needs (respiratory syncytial virus, etc.).
| PHASE I | PHASE II | PHASE III | REGISTRATION | |||
|
Herpes Simplex Virus Type 2
HSV-2 therapeutic vaccine(1) |
Tdap US
Tdap booster |
MenQuadfiTM
Meningococcal ACYW conjugate vaccine, US/EU 6w+ |
MenQuadfiTM
Meningococcal ACYW conjugate vaccine, US 2y+, EU 1y+ |
|||
|
Respiratory syncytial virus
Infants 4-month and older vaccinesGet more information |
Fluzone HD
Pediatric |
VerorabVax® (VRVg) Purified vero rabies vaccine
|
SHAN 6
DTP-HepB-Polio-Hib Pediatric hexavalent vaccine |
|||
|
Yellow Fever
Vaccine produced in vero cells |
Pneumococcal Conjugate Vaccine (PCV)(2)
|
nirsevimab(4)
Respiratory syncytial virusMonoclonal antibodyGet more information |
||||
|
COVID-19 Adjuvanted Recombinant Vaccine(3)
|
| New molecular entities | Additional indications | Publication date: September 2020 |
(1) Developed in collaboration with Immune Design/Merck
(2) Developed in collaboration with SK
(3) Developed in collaboration with GSK
(4) Developed in collaboration with AstraZeneca
Related article
